Compare Heron Therapeutics Inc (HRTX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Vanguard Total International Stock Index Fund ETF trades at $84.49. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | VXUS | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.96 | $87.06 |
52-Week Low | $0.39 | $68.24 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure across 8,700+ stocks in developed and emerging markets. Recent institutional buying includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026 (SEC filing, July 20, 2026). Technical indicators show neutral oscillators with support at $82 and resistance at $84.
VXUS offers cost-effective international diversification at a 0.05% expense ratio, trading at a discount to US equities. Risks include global economic sensitivity and currency fluctuations. Analyst sentiment is mixed with some caution due to inflation concerns, but long-term value exists for investors seeking non-US exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
